Suppr超能文献

全基因组甲基化分析和表观遗传去抑制鉴定肝癌中的肿瘤抑制基因。

Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.

机构信息

Cancer Genome Center, Cold Spring Harbor Laboratory, Woodbury, New York; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Gastroenterology. 2013 Dec;145(6):1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055. Epub 2013 Sep 5.

Abstract

BACKGROUND & AIMS: Epigenetic silencing of tumor suppressor genes contributes to the pathogenesis of hepatocellular carcinoma (HCC). To identify clinically relevant tumor suppressor genes silenced by DNA methylation in HCC, we integrated DNA methylation data from human primary HCC samples with data on up-regulation of gene expression after epigenetic unmasking.

METHODS

We performed genome-wide methylation analysis of 71 human HCC samples using the Illumina HumanBeadchip27K array; data were combined with those from microarray analysis of gene re-expression in 4 liver cancer cell lines after their exposure to reagents that reverse DNA methylation (epigenetic unmasking).

RESULTS

Based on DNA methylation in primary HCC and gene re-expression in cell lines after epigenetic unmasking, we identified 13 candidate tumor suppressor genes. Subsequent validation led us to focus on functionally characterizing 2 candidates, sphingomyelin phosphodiesterase 3 (SMPD3) and neurofilament, heavy polypeptide (NEFH), which we found to behave as tumor suppressor genes in HCC. Overexpression of SMPD3 and NEFH by stable transfection of inducible constructs into an HCC cell line reduced cell proliferation by 50% and 20%, respectively (SMPD3, P = .003 and NEFH, P = .003). Conversely, knocking down expression of these genes with small hairpin RNA promoted cell invasion and migration in vitro (SMPD3, P = .0001 and NEFH, P = .022), and increased their ability to form tumors after subcutaneous injection or orthotopic transplantation into mice, confirming their role as tumor suppressor genes in HCC. Low levels of SMPD3 were associated with early recurrence of HCC after curative surgery in an independent patient cohort (P = .001; hazard ratio = 3.22; 95% confidence interval: 1.6-6.5 in multivariate analysis).

CONCLUSIONS

Integrative genomic analysis identified SMPD3 and NEFH as tumor suppressor genes in HCC. We provide evidence that SMPD3 is a potent tumor suppressor gene that could affect tumor aggressiveness; a reduced level of SMPD3 is an independent prognostic factor for early recurrence of HCC.

摘要

背景与目的

肿瘤抑制基因的表观遗传沉默导致肝细胞癌(HCC)的发病机制。为了确定在 HCC 中由 DNA 甲基化沉默的临床相关肿瘤抑制基因,我们将人类原发性 HCC 样本的 DNA 甲基化数据与基因表达上调后去甲基化的数据进行了整合。

方法

我们使用 Illumina HumanBeadchip27K 阵列对 71 个人 HCC 样本进行了全基因组甲基化分析;数据与 4 种肝癌细胞系在暴露于逆转 DNA 甲基化的试剂(去甲基化)后基因再表达的微阵列分析数据相结合。

结果

基于原发性 HCC 的 DNA 甲基化和去甲基化后细胞系中的基因再表达,我们鉴定出 13 个候选肿瘤抑制基因。随后的验证促使我们专注于功能表征 2 个候选基因,即鞘磷脂磷酸二酯酶 3(SMPD3)和神经丝重链(NEFH),我们发现它们在 HCC 中表现为肿瘤抑制基因。通过稳定转染诱导构建物将 SMPD3 和 NEFH 过表达到 HCC 细胞系中,分别使细胞增殖减少 50%和 20%(SMPD3,P =.003 和 NEFH,P =.003)。相反,用小发夹 RNA 敲低这些基因的表达促进了体外细胞侵袭和迁移(SMPD3,P =.0001 和 NEFH,P =.022),并在皮下注射或原位移植到小鼠后增加了它们形成肿瘤的能力,证实了它们在 HCC 中的肿瘤抑制基因作用。在独立的患者队列中,SMPD3 的低水平与根治性手术后 HCC 的早期复发相关(P =.001;风险比= 3.22;95%置信区间:1.6-6.5 在多变量分析中)。

结论

综合基因组分析确定 SMPD3 和 NEFH 为 HCC 的肿瘤抑制基因。我们提供的证据表明,SMPD3 是一种有效的肿瘤抑制基因,可能影响肿瘤的侵袭性;SMPD3 水平降低是 HCC 早期复发的独立预后因素。

相似文献

1
Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.
Gastroenterology. 2013 Dec;145(6):1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055. Epub 2013 Sep 5.
2
Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma.
J Pathol. 2014 Aug;233(4):392-401. doi: 10.1002/path.4376. Epub 2014 Jun 16.
6
Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
J Korean Med Sci. 2012 Jun;27(6):594-604. doi: 10.3346/jkms.2012.27.6.594. Epub 2012 May 26.
9
Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma.
Clin Cancer Res. 2012 Jul 1;18(13):3541-51. doi: 10.1158/1078-0432.CCR-11-1007. Epub 2012 May 9.
10
Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Cell Biol Int. 2012 May 1;36(5):427-32. doi: 10.1042/CBI20100851.

引用本文的文献

2
Epigenetic Consequences of In Utero PFAS Exposure: Implications for Development and Long-Term Health.
Int J Environ Res Public Health. 2025 Jun 10;22(6):917. doi: 10.3390/ijerph22060917.
3
Reduction of NFX1-123 and HPV 16 E6 and E7 Decreased Telomerase and CENP-F in Cervical Cancer Cell Lines.
Cancers (Basel). 2025 Jun 19;17(12):2044. doi: 10.3390/cancers17122044.
4
SMPD3 as a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Int J Genomics. 2025 Mar 11;2025:5443244. doi: 10.1155/ijog/5443244. eCollection 2025.
5
Sphingomyelin phosphodiesterase 3 as a novel host factor inhibiting hepatitis B virus transcription.
Virol Sin. 2025 Apr;40(2):292-295. doi: 10.1016/j.virs.2025.02.004. Epub 2025 Feb 27.
6
Identification of AK4 and RHOC as potential oncogenes addicted by adult T cell leukemia.
Proc Natl Acad Sci U S A. 2025 Feb 25;122(8):e2416412122. doi: 10.1073/pnas.2416412122. Epub 2025 Feb 21.
7
Prediagnostic Plasma Metabolites Are Associated with Incident Hepatocellular Carcinoma: A Prospective Analysis.
Cancer Prev Res (Phila). 2025 Apr 1;18(4):179-188. doi: 10.1158/1940-6207.CAPR-24-0440.
8
Cell-free DNA methylation-based inflammation score as a marker for hepatocellular carcinoma among people living with HIV.
Hepatol Int. 2025 Jun;19(3):596-606. doi: 10.1007/s12072-024-10768-1. Epub 2024 Dec 20.
10
Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment.
Cancer Immunol Immunother. 2024 May 13;73(7):127. doi: 10.1007/s00262-024-03717-2.

本文引用的文献

1
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.
BMC Bioinformatics. 2013 Apr 15;14:128. doi: 10.1186/1471-2105-14-128.
2
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):34-42. doi: 10.1038/nrgastro.2012.199. Epub 2012 Nov 13.
3
Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
Hepatology. 2012 Nov;56(5):1817-27. doi: 10.1002/hep.25870. Epub 2012 Oct 14.
4
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Cancer Discov. 2011 Dec;1(7):598-607. doi: 10.1158/2159-8290.CD-11-0214. Epub 2011 Nov 9.
5
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions.
Proc Natl Acad Sci U S A. 2012 May 22;109(21):8212-7. doi: 10.1073/pnas.1206062109. Epub 2012 May 7.
6
Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma.
Hepatology. 2012 Sep;56(3):994-1003. doi: 10.1002/hep.25706. Epub 2012 Aug 2.
8
Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review.
Curr Genomics. 2011 Apr;12(2):130-7. doi: 10.2174/138920211795564359.
9
Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma.
Int J Cancer. 2012 Mar 15;130(6):1319-28. doi: 10.1002/ijc.26136. Epub 2011 Jul 21.
10
Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects.
Exp Cell Res. 2011 May 1;317(8):1108-18. doi: 10.1016/j.yexcr.2011.02.011. Epub 2011 Feb 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验